The increased incidence of newly diagnosed cases of prostate cancer following the widespread use of prostate-speci®c antigen (PSA) testing has generated controversy regarding the clinical relevance of PSA-detected tumours. We sought to evaluate the clinical and pathologic characteristics of impalpable PSA-detected (T1c) tumours and their outcome following radical prostatectomy to determine their clinical relevance and compare their characteristics with those of palpable prostate tumours.
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Method
Between 1974 and 1994, 906 patients with either T1c or palpable, clinically organ-con®ned (T2) prostate cancer underwent radical retropubic prostatectomy and pelvic lymph-node dissection. The median age of all patients at the time of surgery was 67 y. The median clinical followup for the cohort was 5.9 y. Pre-and postoperative clinical and pathologic characteristics, and recurrence and survival status, were evaluated.
Results
The clinical stages of the 906 patients were: T1c, 302 patients; T2a, 424 patients; and T2b, 180 patients. The median PSA at diagnosis was 8.4, 7.4 and 9.9 ng/ml for the T1c, T2a and T2b groups, respectively. The distribution of biopsy grade was similar for all three groups, with most tumours in all groups demonstrating moderately differentiated disease. Following radical prostatectomy, the Gleason's score for T1c, T2a and T2b tumours were well to moderately differentiated (scores 2±6) in 65%, 64% and 45%, respectively (P 0.001). Poorly differentiated (score 7±10) lesions were found in 35%, 36%, and 55% for T1c, T2a and T2b, respectively (P 0.001). Organ-con®ned disease was identi®ed in 60%, 56% and 30% (P 0.001); seminal vesicle involvement in 13%, 10% and 23% (P 0.001); lymph node positive disease in 6.7%, 4.3% and 20% (P 0.001); and positive surgical margins in 25%, 21% and 28% for T1c, T2a and T2b lesions, respectively. Disease-free survival at 5 y was 85%, 82% and 73% for T1c, T2a and T2c lesions, respectively.
Conclusion
The impalpable PSA-detected (T1c) prostate tumours represented a group of clinically signi®cant lesions. Over one-third of the T1c lesions were poorly differentiated tumours and demonstrated a similar risk of adverse pathologic features (positive surgical margins, seminal vesicle involvement, and lymph nodes) compared with the palpable (T2a) lesions. Disease-free survival in T1c patients following radical prostatectomy was similar to that observed in patients with T2a lesions and signi®cantly improved compared with patients with larger (T2b) palpable disease.
